Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Decreased methadone effect after ritonavir initiation.

S M Geletko1, A D Erickson

  • 1University of Rhode Island College of Pharmacy, Department of Pharmacy Practice, Veterans Affairs Medical Center, Providence 02908, USA.

Pharmacotherapy
|January 21, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Medication adherence in patients with HIV infection: a comparison of two measurement methods.

The AIDS reader·2003
Same author

Treatment of hyperlipidemia in HIV-infected patients.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2001
Same author

Diabetes mellitus associated with recombinant human growth hormone for HIV wasting syndrome.

Pharmacotherapy·2000
Same author

Improving adherence with complicated medication regimens.

Medicine and health, Rhode Island·1998
Same author

Group education sessions and compliance with nasal CPAP therapy.

Chest·1997
Same author

Electronic compliance assessment of antifungal prophylaxis for human immunodeficiency virus-infected women.

Antimicrobial agents and chemotherapy·1996
Same journal

Comment on "Pharmacokinetic Analysis of Intravenous Push Cefepime in Critically Ill Patients With Sepsis".

Pharmacotherapy·2026
Same journal

Response to Comment on "Pharmacokinetic Analysis of Intravenous Push Cefepime in Critically Ill Patients With Sepsis".

Pharmacotherapy·2026
Same journal

The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male Volunteers.

Pharmacotherapy·2026
Same journal

Menopausal Hormone Therapy: A Narrative Review of Contemporary Evidence.

Pharmacotherapy·2026
Same journal

Getting It Right the Second Time: How Can we Optimize First-Generation Cephalosporin Dosing for Skin and Soft Tissue Infections in the 21st Century?

Pharmacotherapy·2026
Same journal

Buprenorphine Initiation During Extracorporeal Membrane Oxygenation Decreases Sedative and Opioid Exposure: A Retrospective Matched Case-Control Study.

Pharmacotherapy·2026
See all related articles

Ritonavir, a protease inhibitor for HIV, can lower methadone levels, potentially causing withdrawal symptoms in patients undergoing treatment. This highlights significant drug-drug interactions to monitor in co-infected individuals.

Area of Science:

  • Pharmacology
  • Virology
  • Drug Metabolism

Background:

  • Combination antiretroviral therapy (cART) has improved human immunodeficiency virus (HIV) management.
  • Protease inhibitors (PIs) are key components of cART, offering increased potency.
  • Significant drug-drug interactions are a concern with potent antiretroviral agents.

Observation:

  • Methadone, an opioid agonist therapy, is metabolized by cytochrome P450 3A4 (CYP3A4).
  • Ritonavir is a potent inhibitor and inducer of CYP enzymes, including CYP3A4.
  • An HIV-positive patient on methadone maintenance therapy (MMT) experienced withdrawal symptoms.

Findings:

  • The addition of ritonavir to the patient's cART regimen coincided with the onset of withdrawal symptoms.
  • Ritonavir's known effect as a CYP3A4 inducer can decrease methadone plasma levels.

Related Experiment Videos

  • Ritonavir was identified as the most probable cause of reduced methadone efficacy.

    • Implications:

    • Clinicians must be aware of ritonavir's potential to reduce methadone levels in co-treated patients.
    • Monitoring for opioid withdrawal symptoms is crucial in HIV patients receiving both MMT and ritonavir-containing cART.
    • Careful management of drug-drug interactions is essential for optimizing treatment outcomes in coinfection scenarios.